Enzyme Replacement Therapy Market Overview
The enzyme replacement therapy market size was valued at $7,780.69 million in 2020, and is projected to reach $15,166.34 million by 2030, registering a CAGR of 8.3% from 2021 to 2030. Enzyme replacement therapy (ERT) is carried out to replace a missing or deficient enzyme in a person with an inherited enzyme deficiency syndrome. It replenishes the deficient enzymes in the patient’s body either through the intravenous (IV) or oral routes of administration. The IV route is widely accepted by people in which the replacement enzyme is administered directly into the bloodstream through a controlled drip of fluids.
The missing enzyme is replaced by infusions of an enzyme that is purified from human or animal tissue or blood or produced by novel recombinant DNA techniques. The enzyme is altered to allow for a longer half-life; more potent activity; resistance to degradation; or targeting a specific organ, tissue, or cell type. By receiving these enzyme replacements, the body is able to successfully perform the functions inhibited by the deficiency. Enzyme replacement therapies are intended to increase the concentration of enzymes but not for modifying underline root cause of the disease. The first effective treatment with ERT was performed in patients with Gaucher disease, and in last 15 years ERT has become available for other lysosomal storage disorders, including some types of mucopolysaccharidoses (MPS).
The growth of the global enzyme replacement therapy market is majorly driven by rise in prevalence of chronic and life-threatening lysosomal storage diseases such as Gaucher, Pompe, Fabry, and scid. Furthermore, the initiatives taken by the government to increase awareness among people about the availability of ERT is expected to notably contribute toward the growth of the global market. However, high treatment cost and the side effects associated with the therapy significantly hamper the growth of the enzyme replacement therapy market.
New developments in therapies and increase in product pipeline analysis are expected to provide remunerative opportunities for the expansion of the enzyme replacement therapy market. In addition, the healthcare industry in emerging economies is developing at a significant rate, due to surge in demand for enhanced healthcare services, significant investments by government to improve healthcare infrastructure, and development of the medical tourism industry in emerging countries.
The global enzyme replacement therapy market is segmented into product, disease type, end user, and region. Depending on product, the market is categorized into agalsidase beta, imiglucerase, velaglucerase alfa, idursulfase, galsulfase, laronidase, and others. On the basis of disease type, it is segregated into Gaucher disease, Fabry disease, Pompe disease, mucopolysaccharidosis, exocrine pancreatic insufficiency (EPI), and others. By end user, it is fragmented into hospitals and infusion centers & home healthcare setting. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
COVID-19 Impact
Coronavirus (COVID-19) was recognized in late December in Hubei province of Wuhan city in China. This highly contagious disease, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is transmitted among humans. The COVID-19 pandemic has resulted in nationwide lockdown, thereby impacting every industry vertical. According to the report of the United Nations Human Rights, the COVID-19 pandemic has threatened all the members of the society. As a result, health care systems are affected, and the effective delivery of medical care and treatment to all patients have become a challenge worldwide. The COVID-19 pandemic is an unprecedented global public health challenge. During the pandemic, global healthcare systems faced many difficult challenges due to severe shortage of hospital beds & medical equipment. The impact of COVID-19 on 3D enzyme replacement therapy was negative during pandemic. Lysosomal storage diseases are considered to be high risk due to respiratory, renal, and cardiac involvement. For some types of MPS, ERT has been shown to improve respiratory and cardiac function, alleviate organomegaly, improve range of motion, and provide a better health-related quality of life. Enzyme replacement therapy in Pompe disease (glycogen storage disease type 2) improves cardiomyopathy and cardiac functions. It has been observed that it can reduce neuropathic pain and alleviates gastrointestinal symptoms and improves pulmonary functions in Fabry disease. The COVID-19 pandemic has resulted in decreased public mobility, as well as impacted the diagnostic industries. Several diagnostic procedures and therapies that are non-emergent were put on hold to prevent the transmission of the novel coronavirus. Unfortunately, scheduled ERT’s during COVID-19 were disrupted due the stringent lockdown norms. Lately, there is not sufficient personal protective equipment (PPE) for hospital workers on the front lines during the global health crisis. Hospitals were under pressure by the increasing number of patients and lack of personal protective equipment, including face masks, gloves, eye protection, and clothing.
Product segment review
Depending on product, the agalsidase beta segment dominated the enzyme replacement therapy market, due to rise in prevalence of chronic and life-threatening lysosomal storage diseases.
By Product
Others segment held a dominant position in 2020 and would continue to maintain the lead over the forecast period.
Disease segment review
On the basis of disease, the mucopolysaccharidosis segment was the major revenue contributor, owing to increase in incidence of rare diseases.
By Disease
Mucopolysaccharidosis segment is projected as one of the most lucrative segment.
End-user segment review
By end user, the hospitals segment held the largest market share in 2020, and is expected to continue this trend during the forecast period. This is attributed to the fact that people get more support from healthcare professionals & experts, closer monitoring, greater safety, and availability of trained professionals having utmost experience in performing critical infusions..
By End User
Hospitals segment held a dominant position in 2020 and would continue to maintain the lead over the forecast period.
Region segment review
North America is serves as the prominent market for enzyme replacement therapy, and is expected to dominate throughout the forecast period. This is attributed to the availability of infusion centers, increase in acceptance of newer therapies, and rise in prevalence of enzyme deficiency in the region.
By Region
North America was holding a dominant position in 2020 and would continue to maintain the lead over the analysis period.
Key Market Players
- Abbvie Inc.
- Astrazeneca Plc
- Biomarin Pharmaceutical In
- Chiesi Farmaceutici S.P.A.
- Digestive Care, Inc.
- Leadiant Biosciences, Inc.
- Nestle Health Science
- Pfizer Inc.
- Sanofi
- Takeda Pharmaceuticals
Key Benefits For Stakeholders
- This report provides a detailed quantitative analysis of the current enzyme replacement therapy market trends and forecast estimations from 2020 to 2030, which assists to identify the prevailing market opportunities.
- An in-depth market analysis includes analysis of various regions, which is anticipated to provide a detailed understanding of the current trends to enable stakeholders formulate region-specific plans.
- A comprehensive analysis of factors that drive and restrain the growth of the global is provided.
- The projections in this report are made by analyzing the current trends and future market potential from 2021 to 2030, in terms of value.
- An extensive analysis of various regions provides insights that are expected to allow companies to strategically plan their business moves.
- Key market players within the enzyme replacement therapy market are profiled in this report and their strategies are analyzed thoroughly, which helps in understanding competitive outlook of the enzyme replacement therapy market.
Key Market Segments
By Product
- Agalsidase Beta
- Imiglucerase
- Velaglucerase Alfa
- Idursulfase
- Galsulfase
- Laronidase
- Others
By Disease
- Gaucher Disease
- Fabry Disease
- Pompe Disease
- Mucopolysaccharidosis
- Exocrine Pancreatic Insufficiency (EPI)
- Others
By End User
- Hospitals
- Infusion Centers & Home Healthcare Setting
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- Italy
- France
- UK
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
Enzyme Replacement Therapy Market Report Highlights
| Aspects | Details |
 By Product |
|
 By Disease |
|
 By End User |
|
 By Region |
|
Analyst Review
Lysosomal storage disorders are rare conditions caused by an inborn error of metabolism that results in the absence or deficiency of an enzyme, leading to the inappropriate accumulation of material in various cells of the body. Furthermore, this condition is marked by symptoms such as organ enlargement including heart, spleen, and liver. Other symptoms include skin rashes, burning pains in hand and feet, lung dysfunction, damage to central nervous system, and muscle weakness.
Surge of enzyme replacement therapy across the world is majorly attributed to lack or malfunctioning of certain enzymes present in the body. These lysosomal storage disorders are generally genetic in nature and if not diagnosed and treated properly can turn into severe health conditions. Furthermore, increase in government initiatives for production of drugs for ERT and the launch of its pipeline products are anticipated to boost the expansion of the narcolepsy drug market.
Presently, the agalsidase beta dominates the enzyme replacement therapy market, owing to factors such as rise in prevalence of chronic and life-threatening lysosomal storage diseases and government initiatives to increase awareness among people about the availability of ERT.
North America dominates the global enzyme replacement therapy market in 2020, owing to widespread availability & ease of infusion centers, increase in acceptance of newer therapies and rise in prevalence of enzyme deficiency in the region.
The total market value of Enzyme Replacement Therapy Market is $7,780.69 million in 2020
The forecast period in the report is from 2021 to 2030
The market value of Enzyme Replacement Therapy Market in 2030 is $15,166.34 Million
The base year for the report is 2020
Yes, Enzyme Replacement Therapy companies are profiled in the report
The top companies that hold the market share in Enzyme Replacement Therapy Market are Sanofi S.A., Pfizer Inc. ,BioMarin Pharmaceutical Inc., Takeda Pharmaceutical Company Limited, AstraZeneca plc, AbbVie Inc., Inc.,Nestlé S.A. (Nestlé Health Science S.A.), Chiesi Farmaceutici S.p.A., Leadiant Biosciences, Inc., and Digestive Care, Inc.
No, there is no value chain analysis provided in the Enzyme Replacement Therapy Market report
The key trends in the Enzyme Replacement Therapy Market are empowers manufacturers in the medical sector to produce customized products.
Loading Table Of Content...
